Clarifying the Relationship between Delirium and Alzheimer’s Disease and Related Dementias (R01, R21/R33 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) invites applications that focus on clarifying the relationship between delirium and Alzheimer's disease and related dementias (ADRD). Specifically sought is research focusing on understanding why persons with ADRD are at increased risk to develop delirium, often with a worse prognosis compared to those without antecedent ADRD, and why patients who experience delirium are at higher risk to develop subsequent short- and/or long-term mild cognitive impairment or ADRD, often with an accelerated rate of cognitive decline compared to those without preceding delirium. Relevant research projects may focus on, but are not limited to, those that A) provide insight into possible common, sequential, causative, contributory and/or synergistic pathways underlying both ADRD and delirium, B) elucidate mechanisms that lead to the development of delirium against the background of aging and/or neurodegeneration, with particular emphasis on use of appropriate animal models, C) identify risk factors for the onset and/or progression of delirium in those with ADRD and vice versa, D) diagnose and assess one condition in the setting of the other, E) identify putative phenotypes of patients with co-existing ADRD and delirium, or F) test pharmacologic and/or non-pharmacologic strategies to prevent, treat, or reduce the impact of delirium in patients with ADRD and vice versa. Research supported by this FOA is intended to provide mechanistic insight to improve risk assessment, diagnosis, phenotyping, prevention, and management approaches for both delirium and ADRD.

Although this funding opportunity uses the R01 grant mechanism, it runs in parallel with an FOA of identical scientific scope, PAR-18-181, which will use the R21/R33 phased innovation mechanism to conduct exploratory/developmental studies focused on feasibility or proof-of-concept that may then transition to an implementation phase following successful achievement of pre-defined investigator-proposed milestones. 


  • R01 Deadlines: Feb. 5, Jun. 5, Oct. 5
  • R21/R33 Deadlines: Feb. 16, Jun. 16, Oct. 16

PAR-18-029 Expiration Date January 8, 2020




Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

October 5, 2019